Drugs / Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06084286 | Jan 2024 → Oct 2026 expected | neoplastic disease or syndrome | Sichuan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual-targeting CLDN18.2 and PD-L1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06084286 ↗ |
| Modality | Cell therapy | “CLDN18.2/PD-L1 dual-targeting CAR-T cells” NCT06084286 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT06084286 ↗ |